The Recombinant Human EGF Market is expected to reach a value of over USD 19.1 billion by 2028

During the projection period of 2021 to 2028, the Recombinant Human EGF Market is expected to reach a value of over USD 19.1 billion, growing at a CAGR of over 9.3%.

Because recombinant human EGF is used to treat diabetic ulcers, the global recombinant human EGF market is predicted to develop during the forecast period due to an increase in diabetes cases. According to a report issued in September 2019 by the International Diabetes Federation, the global prevalence of diabetes is predicted to be 9.3 percent, but it is expected to rise to 10.2 percent by 2030. According to the same source, the number of individuals suffering from diabetes worldwide is anticipated to rise by 51% by 2045.


The global recombinant human EGF market is predicted to rise due to increased research and development activities by both public and private entities. A study published in the Medical Military Journal in March 2021, for example, looked into the efficacy of recombinant human EGF in wound healing when combined with vacuum sealing drainage (VSD). Both EGF and VSD are important in wound healing, and when administered together, they are said to enhance improved healing. This is believed to assist shorten treatment times by shortening the time it takes for wounds to heal. These advancements are expected to open up new markets for recombinant human EGF.

Coronavirus (COVID – 19) Pandemic Impact on the Global Recombinant Human EGF Market

On December 31, 2019, a COVID-19 epidemic was first detected in Wuhan, China. According to the World Health Organization's Coronavirus (COVID-19) Weekly Epidemiological Update, about 180 million cases and 3.9 million fatalities due to Coronavirus (COVID-19) were documented worldwide up until June 27, 2021.

The COVID-19 pandemic has impacted numerous markets around the world, including the worldwide recombinant human EGF market, where demand and supply are projected to be hampered. The COVID-19 epidemic has caused a slew of surgical procedures to be halted, including a number of non-emergency treatments. According to a 2019 article released by the National Centre for Biotechnology Information, the COVID-19 pandemic caused approximately 1.1 million cases of ophthalmological surgeries in Monte Carlo to come to a halt, with surgical procedures not being completed after registration during the pandemic. The market for recombinant human EGF is predicted to be hampered as a result of this.

Comments

Post a Comment

Popular posts from this blog

YOU YES YOU!

Image
Welcome to Riya's  blog! HEY Everyone! So this is my my very first blog and  i am quite excited about it. WELL  I am  a 21 years old girl who sees the world through her eyes just like everyone else. I believe each of us have their own views and opinions about every little thing that we see through our eyes wide open and that is  what individuality is ! Having our own brains , hobbies,rights,skills , gifts ,flaws and i certainly believe that embracing them is one of the best things a human could do. Okay well so the topic on what  i am going to throw a little  light on here is not self love or self respect or being righteous , strong or anything like that , My topic here is going to be "YOU"   . "YOU" can be anyone here including me 'YOU' = "Individual" Isn't it so weird that in a world having  millions and millions of people  with their own "IDENTITIES " still lack " INDIVIDUALITY ". You know why? because
Read more

Continuous Glucose Monitoring (CGM) Devices Market -Dynamics and Forecast

Image
CGM (Continuous Glucose Monitoring) technology allows you to monitor your glucose levels 24 hours a day using a sensor that delivers the data to a MiniMed insulin pump. However, these devices also aid in diabetes management by lowering individual insulin dosages. These gadgets' integrated software provides users with information about food consumption, medication, physical activity, and ailments.  As a result, an increasing number of diabetic patients are relying on these devices to control and treat their condition, propelling market growth. A growing number of continuous glucose monitoring devices are being integrated with apps and software to treat people with diabetes mellitus, thanks to the development of digital medicines.The rising prevalence of diabetes mellitus has boosted the market for continuous glucose monitoring (CGM) devices. The Continuous Glucose Monitoring (CGM) Market is estimated to develop at a CAGR of 14% over the forecast period. High blood glucose levels oc
Read more

Lack of alternative treatments for epiphora medical disorders is a key restraint on the Nasal Lacrimal Stent Market

Image
A nasolacrimal stent is a tiny tube that is used to treat disorders such as epiphora, as well as dacryocystorhinostomy (DCR) and congenital nasolacrimal blockage. The market for nasal lacrimal stents is predicted to develop as the prevalence of nasolacrimal duct blockage (NLDO), a prevalent lacrimal system condition, rises. For example, according to data published in 2019,  by the NCBI (National Center for Biotechnology Information), the prevalence of nasolacrimal duct obstruction has been found around 6% to 20% in global infants.  Drivers of  Nasal Lacrimal Stent Market Because of continuous research on products to treat Epiphora and Dacryocystorhinostomy disease situations, the nasal lacrimal stent market is likely to grow throughout the forecast period. For example, Alon Kahana of the University of Michigan sponsored a study in October 2019 to assess the safety and efficacy of the slit stent ii lacrimal stents for the treatment of nasolacrimal duct obstruction. In addition, the avai
Read more